All In Biotech

Drug Trial Radar · NCT04971395

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

A Randomized, Double-blind, Placebo Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Jun 25, 2021

Primary completion

Mar 18, 2022

Study completion Mar 18, 2022

Sponsor

Lead sponsor
Xentria, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.

Conditions

  • Healthy Participants

Interventions

  • PlaceboDrug

    Single dose of 2 or 4 mg/kg

  • XTMAB-16 2 mg/kgDrug

    Single dose of 2 mg/kg

  • XTMAB-16 4mg/kgDrug

    Single dose of 4 mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to day 71

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MedStar Harbor Hospital

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.